Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

74.73USD
24 Apr 2019
Change (% chg)

$0.13 (+0.17%)
Prev Close
$74.60
Open
$74.60
Day's High
$75.11
Day's Low
$73.99
Volume
3,947,451
Avg. Vol
3,922,945
52-wk High
$83.81
52-wk Low
$56.26

Select another date:

Mon, Apr 22 2019

Photo

Merck's Keytruda wins FDA approval as combination therapy for kidney cancer

The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.

UPDATE 1-Merck's Keytruda wins FDA approval as combination therapy for kidney cancer

April 22 The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.

Merck's Keytruda wins FDA approval as combination therapy for kidney cancer

April 22 The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.

U.S. FDA approves Roche's small cell lung cancer treatment

March 18 Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb.

French court dismisses damages claims against Merck over thyroid drug

LYON, France A court in the French city of Lyon threw out on Tuesday claims made by 4,113 plaintiffs for damages against Merck over changes to its thyroid drug Levothyrox.

French court dismisses damages claims against Merck over thyroid drug

LYON, France, March 5 A court in the French city of Lyon threw out on Tuesday claims made by 4,113 plaintiffs for damages against Merck over changes to its thyroid drug Levothyrox.

Versum unveils plan to fend off hostile takeover

United States based Versum Materials on Thursday unveiled a plan to prevent a hostile takeover in the face of an unsolicited $5.9 billion offer from Germany's Merck.

UPDATE 1-Versum unveils plan to fend off hostile takeover

* Versum plan designed to stop outsider from taking control (Recasts with details of Versum's plan, adds Merck comment)

AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.

UPDATE 1-AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

Feb 26 British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.

Select another date: